This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Aggarwal N., Breedon A.M.E., Davis C.M., Hwang I.Y., Chang M.W.: Engineering probiotics for therapeutic applications: recent examples and translational outlook. Curr. Opin. Biotechnol.65, 171–179, doi: 10.1016/j.copbio.2020.02.016 (2020)AggarwalN.BreedonA.M.E.DavisC.M.HwangI.Y.ChangM.W.Engineering probiotics for therapeutic applications: recent examples and translational outlookCurr. Opin. Biotechnol.6517117910.1016/j.copbio.2020.02.016202032304955Open DOISearch in Google Scholar
Akdis C.A.: Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat. Rev. Immunol. doi: 10.1038/s41577-021-00538-7 (2021)AkdisC.A.Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions?Nat. Rev. Immunol.10.1038/s41577-021-00538-7202133846604Open DOISearch in Google Scholar
Andrade J.C., Almeida D., Domingos M., Seabra C.L., Machado D., Freitas A.C., Gomes A.M.: Commensal obligate anaerobic bacteria and health: production, storage, and delivery strategies. Front. Bioeng. Biotechnol.8, doi:10.3389/fbioe.2020.00550 (2020)AndradeJ.C.AlmeidaD.DomingosM.SeabraC.L.MachadoD.FreitasA.C.GomesA.M.Commensal obligate anaerobic bacteria and health: production, storage, and delivery strategiesFront. Bioeng. Biotechnol.810.3389/fbioe.2020.005502020729188332582673Open DOISearch in Google Scholar
Bae H.R., Leung P.S.C., Hodge D.L., Fenimore J.M., Jeon S.M., Thovarai V., Dzutsev A., Welcher A.A., Boedigheimer M., Damore M.A., Choi M.S., Fravell R.A. Trinchieri G., Gershwin M.E., Young H.A.: Multi-omics: differential expression of IFN-γ results in distinctive mechanistic features linking chronic inflammation, gut dysbiosis, and autoimmune diseases. J. Autoimmun.111, 102436, doi: 10.1016/j.jaut.2020.102436 (2020)BaeH.R.LeungP.S.C.HodgeD.L.FenimoreJ.M.JeonS.M.ThovaraiV.DzutsevA.WelcherA.A.BoedigheimerM.DamoreM.A.ChoiM.S.FravellR.A.TrinchieriG.GershwinM.E.YoungH.A.Multi-omics: differential expression of IFN-γ results in distinctive mechanistic features linking chronic inflammation, gut dysbiosis, and autoimmune diseasesJ. Autoimmun.11110243610.1016/j.jaut.2020.1024362020726672332220507Open DOISearch in Google Scholar
Barra M., Danino T., Garrido D.: Engineered probiotics for detection and treatment of inflammatory intestinal diseases. Front. Bioeng. Biotechnol.8, 265, doi: 10.3389/fbioe.2020.00265 (2020)BarraM.DaninoT.GarridoD.Engineered probiotics for detection and treatment of inflammatory intestinal diseasesFront. Bioeng. Biotechnol.826510.3389/fbioe.2020.002652020713709232296696Open DOISearch in Google Scholar
Barrientos-Durán A., Fuentes-López A., de Salazar A., Plaza-Díaz J., García F.: Reviewing the composition of vaginal microbiota: inclusion of nutrition and probiotic factors in the maintenance of eubiosis. Nutrients, 12, 419, https://doi.org/10.3390/nu12020419 (2020)Barrientos-DuránA.Fuentes-LópezA.de SalazarA.Plaza-DíazJ.GarcíaF.Reviewing the composition of vaginal microbiota: inclusion of nutrition and probiotic factors in the maintenance of eubiosisNutrients12419https://doi.org/10.3390/nu12020419202010.3390/nu12020419707115332041107Search in Google Scholar
Bezkorovainy A.: Probiotics: determinants of survival and growth in the gut. Am. J. Clin. Nutr.73, 399–405, https://doi.org/10.1093/ajcn/73.2.399s (2001)BezkorovainyA.Probiotics: determinants of survival and growth in the gutAm. J. Clin. Nutr.73399405https://doi.org/10.1093/ajcn/73.2.399s200110.1093/ajcn/73.2.399s11157348Search in Google Scholar
Brüssow H.: Problems with the concept of gut microbiota dysbiosis. Microb. Biotechnol.13, 423–434, doi:10.1111/1751-7915.13479 (2020)BrüssowH.Problems with the concept of gut microbiota dysbiosisMicrob. Biotechnol.1342343410.1111/1751-7915.134792020701782731448542Open DOISearch in Google Scholar
Chang C.J., Lin T.L., Tsai Y.L., Wu T.R., Lai W.F., Lu C.C., Lai H.C.: Next generation probiotics in disease amelioration. J. Food Drug Anal.27, 615–622, doi: 10.1016/j.jfda.2018.12.011 (2019)ChangC.J.LinT.L.TsaiY.L.WuT.R.LaiW.F.LuC.C.LaiH.C.Next generation probiotics in disease ameliorationJ. Food Drug Anal.2761562210.1016/j.jfda.2018.12.011201931324278Open DOISearch in Google Scholar
Corcoran B.M., Ross R.P., Fitzgerald G.F., Dockery P., Stanton C.: Enhanced survival of GroESL-overproducing Lactobacillus paracasei NFBC 338 under stressful conditions induced by drying. Appl. Environ. Microbiol.72, 5104–7, doi: 10.1128/AEM.02626-05 (2006)CorcoranB.M.RossR.P.FitzgeraldG.F.DockeryP.StantonC.Enhanced survival of GroESL-overproducing Lactobacillus paracasei NFBC 338 under stressful conditions induced by dryingAppl. Environ. Microbiol.725104710.1128/AEM.02626-052006148931916820516Open DOISearch in Google Scholar
Da Silva T.F., Casarotti S.N., de Oliveira G.L.V., Penna A.L.B.: The impact of probiotics, prebiotics, and synbiotics on the biochemical, clinical, and immunological markers, as well as on the gut microbiota of obese hosts. Crit. Rev. Food Sci. Nutr.61, 337–355, doi: 10.1080/10408398.2020.1733483 (2021)Da SilvaT.F.CasarottiS.N.de OliveiraG.L.V.PennaA.L.B.The impact of probiotics, prebiotics, and synbiotics on the biochemical, clinical, and immunological markers, as well as on the gut microbiota of obese hostsCrit. Rev. Food Sci. Nutr.6133735510.1080/10408398.2020.1733483202132156153Open DOISearch in Google Scholar
Duong M.T., Qin Y., You S.H., Min J.J.: Bacteria-cancer interactions: bacteria-based cancer therapy. Exp. Mol. Med.51, 12, 1–15, doi: 10.1038/s12276-019-0297-0 (2019)DuongM.T.QinY.YouS.H.MinJ.J.Bacteria-cancer interactions: bacteria-based cancer therapyExp. Mol. Med.511211510.1038/s12276-019-0297-02019690630231827064Open DOISearch in Google Scholar
Eun-Sook L., Eun-Ji S., Young-Do N., So-Young L.: Probiotics in human health and disease: from nutribiotics to pharmabiotics. J. Microbiol.56, 773–782 doi: 10.1007/s12275-018-8293-y (2018)Eun-SookL.Eun-JiS.Young-DoN.So-YoungL.Probiotics in human health and disease: from nutribiotics to pharmabioticsJ. Microbiol.5677378210.1007/s12275-018-8293-y201830353462Open DOISearch in Google Scholar
Ferreira A.K., Mambelli L.I., Pillai S.Y.: Intervening in disease through genetically-modified bacteria. Best Pract. Res. Clin. Gastroenterol.31, 693–697 (2017)FerreiraA.K.MambelliL.I.PillaiS.Y.Intervening in disease through genetically-modified bacteriaBest Pract. Res. Clin. Gastroenterol.31693697201710.1016/j.bpg.2017.09.01729566913Search in Google Scholar
Gałecka M., Basińska A. M., Bartnicka A. Probiotyki – implikacje w praktyce lekarza rodzinnego. Forum Med. Rodz.12, 170–182 (2018)GałeckaM.BasińskaA. M.BartnickaA.Probiotyki – implikacje w praktyce lekarza rodzinnegoForum Med. Rodz.121701822018Search in Google Scholar
Gardiner G.E., O’Sullivan E., Kelly J., Auty M.A., Fitzgerald G.F., Collins J.K., Ross R.P., Stanton C.: Comparative survival rates of human-derived probiotic Lactobacillus paracasei and L. salivarius strains during heat treatment and spray drying. Appl. Environ. Microbiol.66, 2605–2612, doi: 10.1128/aem.66.6.2605-2612.2000 (2000)GardinerG.E.O’SullivanE.KellyJ.AutyM.A.FitzgeraldG.F.CollinsJ.K.RossR.P.StantonC.Comparative survival rates of human-derived probiotic Lactobacillus paracasei and L. salivarius strains during heat treatment and spray dryingAppl. Environ. Microbiol.662605261210.1128/aem.66.6.2605-2612.2000200011058710831444Open DOISearch in Google Scholar
Giron F., Quigley E.M.M.: Pharmabiotic manipulation of the microbiota in gastrointestinal disorders: a clinical perspective. J. Neurogastroenterol. Motil.24, 355–366, doi: 10.5056/jnm18004 (2018)GironF.QuigleyE.M.M.Pharmabiotic manipulation of the microbiota in gastrointestinal disorders: a clinical perspectiveJ. Neurogastroenterol. Motil.2435536610.5056/jnm180042018603466629684976Open DOISearch in Google Scholar
Hwang I.Y., Koh E., Wong A., March J.C., Bentley W.E., Lee Y.S., Chang M.W. Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models. Nat. Commun.8, 15028 doi: 10.1038/ncomms15028 (2017)HwangI.Y.KohE.WongA.MarchJ.C.BentleyW.E.LeeY.S.ChangM.W.Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal modelsNat. Commun.81502810.1038/ncomms150282017539427128398304Open DOISearch in Google Scholar
Jach M., Łoś R., Maj M., Malm A.: Probiotyki – aspekty funkcjonalne i technologiczne. Post. Mikrobiol.52, 161–170 (2013)JachM.ŁośR.MajM.MalmA.Probiotyki – aspekty funkcjonalne i technologicznePost. Mikrobiol.521611702013Search in Google Scholar
Kali A.: Human microbiome engineering: the future and beyond. J. Clin. Diagn. Res.9, DE01-4, doi: 10.7860/JCDR/2015/14946.6570 (2015)KaliA.Human microbiome engineering: the future and beyondJ. Clin. Diagn. Res.9DE01-410.7860/JCDR/2015/14946.65702015460623726500908Open DOISearch in Google Scholar
Kang M., Choe D., Kim K., Cho B.K., Cho S.: Synthetic biology approaches in the development of engineered therapeutic microbes. Int. J. Mol. Sci.21, 8744, doi: 10.3390/ijms21228744 (2020)KangM.ChoeD.KimK.ChoB.K.ChoS.Synthetic biology approaches in the development of engineered therapeutic microbesInt. J. Mol. Sci.21874410.3390/ijms212287442020769935233228099Open DOISearch in Google Scholar
Kramer M.G., Masner M., Ferreira F.A., Hoffman R.M.: Bacterial therapy of cancer: promises, limitations and insights for future directions. Front. Microbiol.9, 16 doi: 10.3389/fmicb.2018.00016 (2018)KramerM.G.MasnerM.FerreiraF.A.HoffmanR.M.Bacterial therapy of cancer: promises, limitations and insights for future directionsFront. Microbiol.91610.3389/fmicb.2018.000162018581026129472896Open DOISearch in Google Scholar
Kumar M., Yadav A.K., Verma V., Singh B., Mal G., Nagpal R., Hemalatha R.: Bioengineered probiotics as a new hope for health and diseases: an overview of potential and prospects. Future Microbiol.11, 585–600 doi: 10.2217/fmb.16.4. (2016)KumarM.YadavA.K.VermaV.SinghB.MalG.NagpalR.HemalathaR.Bioengineered probiotics as a new hope for health and diseases: an overview of potential and prospectsFuture Microbiol.1158560010.2217/fmb.16.4201627070955Open DOISearch in Google Scholar
Landry B.P., Tabor J.J. Engineering diagnostic and therapeutic gut bacteria. Microbiol. Spectr.5, doi: 10.1128/microbiolspec.BAD-0020-2017 (2017)LandryB.P.TaborJ.J.Engineering diagnostic and therapeutic gut bacteriaMicrobiol. Spectr.510.1128/microbiolspec.BAD-0020-2017201729052539Open DOISearch in Google Scholar
Lee J.W., Chan C.T.Y., Slomovic S., Collins J.J. Next-generation biocontainment systems for engineered organisms. Nat. Chem. Biol.14, 530–537, doi: 10.1038/s41589-018-0056-x (2018)LeeJ.W.ChanC.T.Y.SlomovicS.CollinsJ.J.Next-generation biocontainment systems for engineered organismsNat. Chem. Biol.1453053710.1038/s41589-018-0056-x201829769737Open DOISearch in Google Scholar
Lim D., Song M.: Development of bacteria as diagnostics and therapeutics by genetic engineering. J. Microbiol.57, 637–643, doi: 10.1007/s12275-019-9105-8 (2019)LimD.SongM.Development of bacteria as diagnostics and therapeutics by genetic engineeringJ. Microbiol.5763764310.1007/s12275-019-9105-8201931079333Open DOISearch in Google Scholar
Mazhar S.F., Afzal M., Almatroudi A., Munir S., Ashfaq U.A., Rasool M., Raza H., Munir H.M.W., Rajoka M.S.R., Khurshid M.: The prospects for the therapeutic implications of genetically engineered probiotics. J. Food Qual. article ID 9676452 https://doi.org/10.1155/2020/9676452 (2020)MazharS.F.AfzalM.AlmatroudiA.MunirS.AshfaqU.A.RasoolM.RazaH.MunirH.M.W.RajokaM.S.R.KhurshidM.The prospects for the therapeutic implications of genetically engineered probioticsJ. Food Qual.article ID 9676452 https://doi.org/10.1155/2020/9676452202010.1155/2020/9676452Search in Google Scholar
Moloko G.M., Mapitsi S.T.: Probiotic engineering: towards development of robust probiotic strains with enhanced functional properties and for targeted control of enteric pathogens. Gut Pathog.9, 28, doi: 10.1186/s13099-017-0178-9 (2017)MolokoG.M.MapitsiS.T.Probiotic engineering: towards development of robust probiotic strains with enhanced functional properties and for targeted control of enteric pathogensGut Pathog.92810.1186/s13099-017-0178-92017542299528491143Open DOISearch in Google Scholar
Mroczyńska M., Libudzisz Z., Gałęcka M., Szachta P.: Mikroorganizmy jelitowe człowieka i ich aktywność metaboliczna. Prz. Gastroenterol.4, 218–224 (2016)MroczyńskaM.LibudziszZ.GałęckaM.SzachtaP.Mikroorganizmy jelitowe człowieka i ich aktywność metabolicznaPrz. Gastroenterol.4218224201610.5114/pg.2011.24304Search in Google Scholar
Ozdemir T., Fedorec A.J.H., Danino T., Barnes C.P.: Synthetic biology and engineered live biotherapeutics: toward increasing system complexity. Cell Syst.7, 5–16, doi: 10.1016/j.cels.2018.06.008 (2018)OzdemirT.FedorecA.J.H.DaninoT.BarnesC.P.Synthetic biology and engineered live biotherapeutics: toward increasing system complexityCell Syst.751610.1016/j.cels.2018.06.008201830048620Open DOISearch in Google Scholar
Paton A.W, Morona R., Paton J.C. Bioengineered microbes in disease therapy. Trends Mol. Med.18, 417–425, doi: 10.1016/j.molmed.2012.05.006 (2012)PatonA.WMoronaR.PatonJ.C.Bioengineered microbes in disease therapyTrends Mol. Med.1841742510.1016/j.molmed.2012.05.006201222721939Open DOISearch in Google Scholar
Pedrolli D.B., Ribeiro N.V., Squizato P.N., de Jesus V.N., Cozetto D.A: Team AQA Unesp at iGEM 2017. Engineering microbial living therapeutics: the synthetic biology toolbox. Trends Biotechnol.37, 100–115, doi: 10.1016/j.tibtech.2018.09.005 (2019)PedrolliD.B.RibeiroN.V.SquizatoP.N.de JesusV.N.CozettoD.ATeam AQA Unesp at iGEM 2017. Engineering microbial living therapeutics: the synthetic biology toolboxTrends Biotechnol.3710011510.1016/j.tibtech.2018.09.005201930318171Open DOISearch in Google Scholar
Plavec T.V., Berlec A.: Engineering of lactic acid bacteria for delivery of therapeutic proteins and peptides. Appl. Microbiol. Biotechnol.103, 2053–2066, doi: 10.1007/s00253-019-09628-y (2019)PlavecT.V.BerlecA.Engineering of lactic acid bacteria for delivery of therapeutic proteins and peptidesAppl. Microbiol. Biotechnol.1032053206610.1007/s00253-019-09628-y201930656391Open DOISearch in Google Scholar
Pongking T., Haonon O., Dangtakot R., Onsurathum S., Jusakul A., Intuyod K., Sangka A., Anutrakulchai S., Cha’on U., Pinlaor S., Pinlaor P.: A combination of monosodium glutamate and high-fat and high-fructose diets increases the risk of kidney injury, gut dysbiosis and host-microbial co-metabolism. PLoS One, 15, 4, e0231237, doi:10.1371/journal.pone.0231237 (2020)PongkingT.HaononO.DangtakotR.OnsurathumS.JusakulA.IntuyodK.SangkaA.AnutrakulchaiS.Cha’onU.PinlaorS.PinlaorP.A combination of monosodium glutamate and high-fat and high-fructose diets increases the risk of kidney injury, gut dysbiosis and host-microbial co-metabolismPLoS One154e023123710.1371/journal.pone.02312372020714166732267892Open DOISearch in Google Scholar
Ropot A.V., Karamzin A.M., Sergeyev O.V.: Cultivation of the next-generation probiotic akkermansia muciniphila, methods of its safe delivery to the intestine, and factors contributing to its growth in vivo. Curr. Microbiol.77, 8, 1363–1372, doi: 10.1007/s00284-020-01992-7 (2020)RopotA.V.KaramzinA.M.SergeyevO.V.Cultivation of the next-generation probiotic akkermansia muciniphila, methods of its safe delivery to the intestine, and factors contributing to its growth in vivoCurr. Microbiol.7781363137210.1007/s00284-020-01992-7202032318863Open DOISearch in Google Scholar
Rottinghaus A.G., Amrofell M.B., Moon T.S.: Biosensing in smart engineered probiotics. Biotechnol. J.15, e1900319, doi: 10.1002/biot.201900319 (2020)RottinghausA.G.AmrofellM.B.MoonT.S.Biosensing in smart engineered probioticsBiotechnol. J.15e190031910.1002/biot.2019003192020730504831860168Open DOISearch in Google Scholar
Ruszkowski J., Szewczyk A., Witkowski J. M.: Przegląd doustnych prebiotyków, probiotyków, synbiotyków i postbiotyków dostępnych na polskim rynku aptecznym. Farm. Pol.74, 2, 114–122 (2018)RuszkowskiJ.SzewczykA.WitkowskiJ.M.Przegląd doustnych prebiotyków, probiotyków, synbiotyków i postbiotyków dostępnych na polskim rynku aptecznymFarm. Pol.742114122201810.32383/farmpol/119464Search in Google Scholar
Sharma R., Gupta D., Mehrotra R., Mago P.: Psychobiotics: the next-generation probiotics for the brain. Curr. Microbiol.78, 2, 449–463, doi: 10.1007/s00284-020-02289-5 (2021)SharmaR.GuptaD.MehrotraR.MagoP.Psychobiotics: the next-generation probiotics for the brainCurr. Microbiol.78244946310.1007/s00284-020-02289-5202133394083Open DOISearch in Google Scholar
Sheehan V.M., Sleator R.D., Fitzgerald G.F., Hill C.: Heterologous expression of BetL, a betaine uptake system, enhances the stress tolerance of Lactobacillus salivarius UCC118. Appl. Environ. Microbiol.72, 3, 2170–2177, doi: 10.1128/AEM.72.3.2170-2177.2006 (2006)SheehanV.M.SleatorR.D.FitzgeraldG.F.HillC.Heterologous expression of BetL, a betaine uptake system, enhances the stress tolerance of Lactobacillus salivarius UCC118Appl. Environ. Microbiol.7232170217710.1128/AEM.72.3.2170-2177.20062006139318316517668Open DOISearch in Google Scholar
Skrzydło-Radomańska B., Wronecki J.: Czy mikrobiotę jelitową można skutecznie modyfikować? Varia Medica, 3, 1, 18–26 (2019)Skrzydło-RadomańskaB.WroneckiJ.Czy mikrobiotę jelitową można skutecznie modyfikować?Varia Medica3118262019Search in Google Scholar
Sleator R.D., Hill C.: Rational design of improved pharmabiotics. J. Biomed. Biotechnol. 275287, doi: 10.1155/2009/275287 (2009)SleatorR.D.HillC.Rational design of improved pharmabioticsJ. Biomed. Biotechnol.27528710.1155/2009/2752872009274264719753318Open DOISearch in Google Scholar
Sola-Oladokun B., Culligan E.P., Sleator R.D.: Engineered probiotics: applications and biological containment. Annu. Rev. Food Sci. Technol.28, 8, 353–370, doi: 10.1146/annurev-food-030216-030256 (2017)Sola-OladokunB.CulliganE.P.SleatorR.D.Engineered probiotics: applications and biological containmentAnnu. Rev. Food Sci. Technol.28835337010.1146/annurev-food-030216-030256201728125354Open DOISearch in Google Scholar
Tan Y., Shen J., Si T., Ho C.L., Yinqing Li Y., Dai L.: Engineered live biotherapeutics: progress and challenges. Review Biotechnol. J.15, 10, e2000155, doi: 10.1002/biot.202000155 (2020)TanY.ShenJ.SiT.HoC.L.Yinqing LiY.DaiL.Engineered live biotherapeutics: progress and challengesReview Biotechnol. J.1510e200015510.1002/biot.202000155202032770635Open DOISearch in Google Scholar
Thursby E., Juge N.: Introduction to the human gut microbiota. Biochem. J.474, 1823–1836, doi: https://doi.org/10.1042/BCJ20160510 (2017)ThursbyE.JugeN.Introduction to the human gut microbiotaBiochem. J.47418231836https://doi.org/10.1042/BCJ20160510201710.1042/BCJ20160510543352928512250Search in Google Scholar
Tyagi P., Tasleem M., Prakash S., Chouhan G.: Intermingling of gut microbiota with brain: exploring the role of probiotics in battle against depressive disorders. Food Res. Int.137, 109489, doi: 10.1016/j.foodres.2020.109489 (2020)TyagiP.TasleemM.PrakashS.ChouhanG.Intermingling of gut microbiota with brain: exploring the role of probiotics in battle against depressive disordersFood Res. Int.13710948910.1016/j.foodres.2020.109489202033233143Open DOISearch in Google Scholar
Vallianou N., Stratigou T., Christodoulatos G.S., Tsigalou C., Dalamaga M.: Probiotics, prebiotics, synbiotics, postbiotics, and obesity: current evidence, controversies, and perspectives. Curr. Obes. Rep.9, 179–192, https://doi.org/10.1007/s13679-020-00379-w (2020)VallianouN.StratigouT.ChristodoulatosG.S.TsigalouC.DalamagaM.Probiotics, prebiotics, synbiotics, postbiotics, and obesity: current evidence, controversies, and perspectivesCurr. Obes. Rep.9179192https://doi.org/10.1007/s13679-020-00379-w202010.1007/s13679-020-00379-w32472285Search in Google Scholar
Vandenplas Y., Huys G., Daube G.: Probiotics: an update. J. Pediatr. (Rio J.), 91, 6–21, doi: 10.1016/j.jped.2014.08.005. Epub 2014 Oct 23. (2015)VandenplasY.HuysG.DaubeG.Probiotics: an updateJ. Pediatr. (Rio J.)9162110.1016/j.jped.2014.08.005Epub 2014 Oct 23.201525458874Open DOISearch in Google Scholar
Wieërs G., Belkhir L., Enaud R., Leclercq S., Philippart de Foy J.M., Dequenne I., de Timary P., Cani P.D.: How probiotics affect the microbiota. Front. Cell Infect. Microbiol.9, 454, doi:10.3389/fcimb.2019.00454 (2020)WieërsG.BelkhirL.EnaudR.LeclercqS.Philippart de FoyJ.M.DequenneI.de TimaryP.CaniP.D.How probiotics affect the microbiotaFront. Cell Infect. Microbiol.945410.3389/fcimb.2019.004542020697444132010640Open DOISearch in Google Scholar
Wilkins L.J., Monga M., Miller A.W.: Defining dysbiosis for a cluster of chronic diseases. Sci. Rep.9, 12918, doi:10.1038/s41598-019-49452-y (2019)WilkinsL.J.MongaM.MillerA.W.Defining dysbiosis for a cluster of chronic diseasesSci. Rep.91291810.1038/s41598-019-49452-y2019673386431501492Open DOISearch in Google Scholar
Wu C., Huang J., Zhou R.: Genomics of lactic acid bacteria: current status and potential applications. Crit. Rev. Microbiol.43, 393–404, doi: 10.1080/1040841X.2016.1179623 (2017)WuC.HuangJ.ZhouR.Genomics of lactic acid bacteria: current status and potential applicationsCrit. Rev. Microbiol.4339340410.1080/1040841X.2016.1179623201728502225Open DOISearch in Google Scholar
Yadav R., Kumar V., Baweja M., Shukla P.: Gene editing and genetic engineering approaches for advanced probiotics: a review. Crit. Rev. Food Sci. Nutr.58, 1735–1746, doi: 10.1080/10408398.2016.1274877 (2018)YadavR.KumarV.BawejaM.ShuklaP.Gene editing and genetic engineering approaches for advanced probiotics: a reviewCrit. Rev. Food Sci. Nutr.581735174610.1080/10408398.2016.1274877201828071925Open DOISearch in Google Scholar
Yadav M., Shukla P.: Efficient engineered probiotics using synthetic biology approaches: a review. Biotechnol. Appl. Biochem.67, 22–29, doi: 10.1002/bab.1822 (2020)YadavM.ShuklaP.Efficient engineered probiotics using synthetic biology approaches: a reviewBiotechnol. Appl. Biochem.67222910.1002/bab.1822202031538358Open DOISearch in Google Scholar
Yadav M., Shukla P.: Recent systems biology approaches for probiotics use in health aspects: a review. 3 Biotech.9, 448, doi: 10.1007/s13205-019-1980-5 (2019)YadavM.ShuklaP.Recent systems biology approaches for probiotics use in health aspects: a review3 Biotech.944810.1007/s13205-019-1980-52019684828731763126Open DOISearch in Google Scholar
Yao M., Xie J., Du H., McClements D.J., Xiao H., Li L.: Progress in microencapsulation of probiotics: a review. Compr. Rev. Food Sci. Food Saf.19, 2, 857–874, doi: 10.1111/1541-4337.12532 (2020)YaoM.XieJ.DuH.McClementsD.J.XiaoH.LiL.Progress in microencapsulation of probiotics: a reviewCompr. Rev. Food Sci. Food Saf.19285787410.1111/1541-4337.12532202033325164Open DOISearch in Google Scholar
Zhou Z., Chen X., Sheng H., Shen X., Sun X., Yan Y., Wang J., Yuan Q.: Engineering probiotics as living diagnostics and therapeutics for improving human health. Microb. Cell Fact.19, 56, doi: 10.1186/s12934-020-01318-z (2020)ZhouZ.ChenX.ShengH.ShenX.SunX.YanY.WangJ.YuanQ.Engineering probiotics as living diagnostics and therapeutics for improving human healthMicrob. Cell Fact.195610.1186/s12934-020-01318-z2020705504732131831Open DOISearch in Google Scholar
Zou Y., Chen T.: Engineered akkermansia muciniphila: a promising agent against diseases. Exp. Ther. Med.20, 285, doi: 10.3892/etm.2020.9415 (2020)ZouY.ChenT.Engineered akkermansia muciniphila: a promising agent against diseasesExp. Ther. Med.2028510.3892/etm.2020.94152020766813033209129Open DOISearch in Google Scholar
Zuo F., Chen S., Marcotte H.: Engineer probiotic bifidobacteria for food and biomedical applications – current status and future prospective. Review Biotechnol. Adv.45, 107654, doi: 10.1016/j.biotechadv.2020.107654 (2020)ZuoF.ChenS.MarcotteH.Engineer probiotic bifidobacteria for food and biomedical applications – current status and future prospectiveReview Biotechnol. Adv.45107654,10.1016/j.biotechadv.2020.107654202033159984Open DOISearch in Google Scholar